View More Recent Stories
-
2Q24 U.S. biotech earnings preview
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $357 at Canaccord Genuity
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $288 at UBS
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $295 at Stifel
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $265 at RBC Capital, 'we remain buyers'
-
Increasing unusual call option volume: ALNY ZI MCRB BURL FTAI BRCC ENVX OLLI
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $282 at TD Cowen
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $250 at Morgan Stanley
-
Midday movers: Apple, Eli Lilly rise; Coinbase falls
-
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'
-
Alnylam Pharma (ALNY) out of the money July puts and January 260 calls active as share price up 38%
-
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
-
BMO Capital Reiterates Outperform Rating on Alnylam (ALNY), Sees Significant Upside Following Data
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran
-
Alnylam Pharma (ALNY) to Resume Trading at 7:30 a.m.
-
BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive Data
-
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Top pharma stocks to own in 2024 – Citi

